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The rise of the NGF mRNA pool which takes place following exposure of L-929 fibroblasts to serum was prevented in the presence of 5 PM 
K-252a, a compound which inhibits several species of protein kinase activities. To characterize further this phenomenon, L-929 cells growing in 
a serum-free medium were exposed to cyclic nucleotide analogs, to a divafent cation ionophore or to the phorbol ester PMA. Onfy this latter com- 
pound induced an enhan~ment of the NGF mRNA pool, suggesting an involvement of protein kinase C in the upregulation of the NGF transcripts. 
The effects of PMA or serum also require a synthesis of protein since the level of NGF transcripts remained stable in the presence of cycloheximide. 
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1. INTRODUCTION 
Nerve growth factor (NGF) is a neurotrophic protein 
which supports the survival and promotes the terminal 
differentiation of several types of peripheral and cen- 
tral neurons [I]. In vivo, levels of expression of the 
NGF gene are tissue-specific and developmentally 
regulated [2-61. However, the molecular mechanisms 
involved in the control of the synthesis of NGF remain 
largely unknown. Studies performed in vitro with 
NGF-producing L-929 ~broblasts have provided 
evidence for a regulatory role of some effector 
molecules, such as glucocorticoids or retinoic acid, 
which decrease and increase, respectively, the cellular 
levels of NGF mRNA [7-91. 
L-929 fibroblasts have also been shown to respond to 
serum, which enhances the steady state level of NGF 
mRNA by a factor of about 5-fold flO,ll]. This effect 
of serum on the transcription or stability of NGF 
mRNA is not restricted to L-929 cells, as it has also 
been observed in primary fibroblasts or iris transplants 
1121. 
Polypeptide hormones or growth factors are known 
to mediate their effect through secondary messengers. 
Cyclic nucleotide synthesis, calcium mobilization or 
diacylglycerol production may cause an activation of 
specific protein kinases which play a critical role in cell 
responsiveness [ 131. Therefore, we have investigated 
whether the effect of serum on the cellular level of NGF 
mRNA could be impaired by a protein kinase inhibitor. 
Alternatively, cells grown in the absence of serum were 
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exposed to various compounds known to activate dif- 
ferent types of protein kinases, in order to determine if 
they could increase the NGF mRNA pool. 
2. MATERIALS AND METHODS 
L-929 fibroblasts were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 5% horse serum. Cells were 
plated in 10 cm diameter dishes at an initial density of IO3 cells/cm’. 
After 16 h, the medium was replaced by a serum-free mixture made 
of DMEM and F12 media (3: 1 v/v) containing ins&in (5 pg/ml), 
transferrin (5 Itglml) and selenium ions (2.5 x lo-’ M). After 3 days, 
the serum-free medium was renewed, and cells were exposed to the 
additives listed in table 1. 
Cells were collected after 8 h of treatment and total RNA was ex- 
tracted by the LiCl/urea procedure [14]. Amounts of poly(A)+ RNA 
were estimated by hybridization with [3H]poly(U), followed by 
RNase digestion and TCA precipitation [lo]. Glyoxylated RNA 
samples containing identical amounts of poly(A)+ RNA were frac- 
tionated on agarose gels, transferred to a nylon membrane and 
hybridized with a NGF cDNA probe 1151 previously labelled by nick 
translation. After several washes of the filters, radioactivity 
associated with the NGF mRNA was revealed by radioautography, 
and relative levels calculated by densitometric analysis. 
Cyclic nucfeotide analogs, PMA, ionophore AZ3187, forskolin, in- 
sulin and transferrin were purchased from Sigma Chemicals (France); 
K-252a was the kind gift of Dr Y. Matsuda (Kyowa Hakko Kogyo 
Co., Japan) while [3H]poly(U), [32P]dCTP and the nick translation 
kit were obtained from Amersham (UK). Culture media were from 
Gibco (France) and tissue culture dishes from Nunc (Denmark). 
3. RESULTS 
3.1. The protein kinase inhibitor K-252a counteracts 
the effect of serum 
K-252a is an inhibitor of protein kinase C, as well as 
of cyclic AMP- or cyclic GMP-dependent protein 
kinases [ 161, thus providing a tool to investigate 
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whether the stimulation of NGF synthesis depends on 
either of these enzymatic activities. L-929 cells main- 
tained in serum-free medium for 3 days were exposed 
to K-252a during 1 h, and serum was added to the 
growth medium 1 h later. After 8 h of incubation, 
mRNAs were extracted and subjected to Northern blot 
analysis. Data presented in fig. 1A and table 1 show that 
the increase of NGF mRNA pool elicited by serum is 
abolished in the presence of the kinase inhibitor. 
3.2. PMA mimicks the effect of serum 
In order to characterize which of the different kinase 
activities inhibited by K-252a mediates the effect of 
serum, NGF mRNA levels were measured in L-929 cells 
following exposure for 8 h to cyclic nucleotide analogs, 
to the divalent cation ionophore A23187 or to PMA. 
The effect of forskolin, an activator of adenylate 
cyclase, was also investigated. A typical Northern blot 
is presented in fig.lB, while the results of the den- 
sitometric analyses are summarized in table 1. They 
demonstrate a 4-fold stimulatory effect of 10m6 M 
PMA. In contrast, forskolin, 8-bromo-cyclic AMP or 
ionophore A23 187 did not have any effect on the steady 
state level of NGF mRNA, at least at the concentra- 
tions tested in these experiments. 8-Bromo-cyclic GMP 
had a weak stimulatory action. A23187, forskolin or 
8-bromo-cyclic GMP, present at the concentrations 
listed in table 1, did not have any synergistic effect 
when added together with 1 pM PMA (not shown). 
Unlike PMA, the unesterified compound 4-a phorbol, 
which has no kinase C activating activity, was without 
effect on the NGF mRNA level. 
3.3. Requirement for a protein synthesis 
In order to assess whether PMA and serum may 
modify the level of NGF mRNA in the absence of pro- 
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Fig. 1. Northern blot analysis of the NGF mRNA of L-929 cells. (A) 
The protein kinase inhibitor K-252a counteracts the effect of serum. 
RNAs were extracted from cells growing in serum-free medium (I), 
or exposed to 5% horse and 5% fetal calf serum plus 0.5 PM K-252a 
(2), to serum alone (3 and 5), or to serum and 5 CM K-252a (4). (B) 
PMA mimicks the effect of serum. RNAs were from cells growing in 
serum-free medium (l), or exposed to 1 pM PMA (2), 10 mM 
I-bromo-cyclic AMP (3), 2.8 mM I-bromo-cyclic GMP (4), 5% 
horse and 5% fetal calf serum (5) or 0.1 hM A23187 (6). (C) 
Cycloheximide prevents the effect of serum and PMA. RNAs were 
extracted from cells exposed for 8 h to 5% horse and 5% fetal calf 
serum (l), the same and 35 PM cycloheximide (2), 1 pM PMA (3), or 
1 PM PMA and 35 ,uM cycloheximide (4). 
Table 1 
Levels of NGF transcripts in L-929 fibroblasts 
Culture conditions Relative levels of 
NGF mRNA +_ SD 
(n) 
Serum-free medium, no additive 1 (11)s 
PMA (1 ,uM) 4.10 f 0.87 (11) 
I-Bromo-cyclic AMP (10 mM) 1.08 f 0.48 (2) 
Forskolin (1 ,uM) 0.90 f 0.00 (2) 
8-Bromo-cyclic GMP (2.8 mM) 1.86 f 0.75 (3) 
A23187 (0.1 ,uM) 1.21 f 0.50 (3) 
Horse serum (5%) + fetal calf serum (5%) 8.13 f 6.70 (9) 
Horse serum (5%) + fetal calf serum (5%) + 
K-252a (5 PM) 
Horse serum 5% + fetal calf serum (5%) + 
1.2 f 0.56 (2) 
cycloheximide (35 PM) 1.46 f 0.35 (3) 
PMA (1 PM) + cycloheximide (35 FM) 1.53 + 0.35 (3) 
4_cr-Phorbol (1 PM) 0.99 * 0.15 (3) 
a A value of 1 was given to the relative level found in cells cultured 
in serum-free medium 
tein synthesis, cells grown in serum-free medium were 
exposed to 10m6 M PMA or 5% horse and fetal calf 
serum, in the absence or presence of 35 gM cyclohex- 
imide. The protein synthesis inhibitor prevented the rise 
of NGF mRNA pool (fig.lC). 
4. DISCUSSION 
Addition of serum to L-929 cells or to primary 
fibroblasts induces a specific increase of the level of 
NGF-mRNA [lo-121. We have proposed that the 
serum effect observed in vitro reflects a wound 
mechanism, which could take place in vivo in response 
to vasculature disruption [ 121. It was interesting, in this 
context, to investigate the chemical nature of the in- 
tracellular signal which transduces the stimulatory ac- 
tion of serum elements. The response of L-929 cells to 
serum is prevented in the presence of K-252a, a com- 
pound which impairs the activity of several types of 
protein kinases [16]. Conversely, a 4-fold increase of 
the pool of NGF mRNA was observed upon addition 
of PMA to L-929 cells growing in serum-free medium. 
PMA is known to activate the calcium and 
phospholipid-dependent protein kinase C [ 171. This, 
and the fact that the unesterified compound 4-c~ phor- 
bol did not influence the NGF mRNA pool suggest an 
involvement of protein kinase C in the up regulation of 
NGF transcripts. These data raise also the possibility 
that serum factors promoting NGF synthesis may act 
through this enzyme family. 
In contrast, our results suggest hat cyclic nucleotide 
or calcium and calmodulin-dependent protein kinases 
do not influence the pool of NGF transcripts in L-929 
fibroblasts. In this respect, L-929 cells appear different 
from C6 glioma cells, in which the NGF mRNA levels 
are regulated by a cyclic AMP-dependent mechanism 
43 
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[18]. It should be stressed, however, that this CAMP- 
dependent process was observed in a serum-containing 
medium, and that serum was reported to enhance the 
amount of NGF protein released by C6 glioma cells [ 191 
as well as by astrocytes [20]. Thus, it is possible that the 
serum-mediated regulation of the NGF mRNA, via 
kinase C, may operate in these cells too. 
Use of cycloheximide indicated that transduction of 
the signal triggered by the presence of serum or PMA 
requires protein synthesis. It seems possible, therefore, 
that together with a protein kinase C-dependent pro- 
cess, activation of hitherto silent genes, such as pro- 
tooncogenes, is also involved in the cascade of events 
leading to a modification of the NGF mRNA pool. 
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